By Adria Calatayud

Sanofi appointed Brian Foard, who has helmed the launch of its blockbuster anti-inflammatory drug Dupixent, as permanent head of its specialty-care business unit and member of its executive committee.

Foard, who has more than 20 years of experience in the industry, has been interim head of the unit since September while also serving as head of specialty care in North America and U.S. country lead, the French pharmaceutical company said Tuesday.

He joined the company in 2017 and began his career with Galderma, Sanofi said.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

January 09, 2024 01:59 ET (06:59 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Sanofi 차트를 더 보려면 여기를 클릭.
Sanofi (NASDAQ:SNY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Sanofi 차트를 더 보려면 여기를 클릭.